ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
Gynecologic Oncology
Volume 104, Issue 1, January 2007, Pages 212-216
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (323 K)

 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.ygyno.2006.07.045    How to Cite or Link Using DOI (Opens New Window)
Copyright © 2006 Elsevier Inc. All rights reserved.

Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?

Giovanni D. Alettia, Harry J. Longb, Karl C. Podratza and William A. Clibya, Corresponding Author Contact Information, E-mail The Corresponding Author

aDivision of Gynecologic Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA bDivision of Medical Oncology, Mayo Clinic, Rochester, MN, USA

Received 22 May 2006. 
Available online 4 October 2006.

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Abstract

Objectives

Clinicians often question when to start chemotherapy after patients undergo surgery for ovarian cancer. A major unproven concern is whether a long postoperative delay reduces the benefits of an extensive procedure and leads to disease progression. Our objectives were to evaluate the correlation between clinical and pathologic variables and to evaluate the effect of the “time to chemotherapy” (TTC) interval on survival.

Methods

We retrospectively studied data from 218 patients with International Federation of Gynecology and Obstetrics stage IIIC or IV ovarian cancer (TNM stage T3c or T4) who were consecutively treated between January 1, 1994, and December 31, 1998.

Results

Mean age at diagnosis was 64 years (range, 24–87 years; median, 65 years), and 206 patients received postoperative platinum-based chemotherapy. Mean TTC interval was 26 days (range, 7–79 days; median, 25 days). No correlation was found between operative time and TTC interval length (P = 0.99). Age and performance of rectosigmoidectomy were correlated with longer TTC interval (P = 0.009 and P = 0.005, respectively), but TTC was not a predictor of overall survival (odds ratio, 1.00; 95% confidence interval, 0.98–1.01; P = 0.85). Differences in TTC interval length (≤ 17 days, 18–26 days, 27–33 days, or ≥ 34 days) did not affect survival (P = 0.93). Even after categorizing patients by residual disease (< 1 cm or  ≥ 1 cm), no statistically significant effect of TTC on prognosis was identified.

Conclusions

Concerns about the TTC interval should not be used to justify spending less time in the operative arena or using a more conservative approach for patients with advanced ovarian cancer.

Keywords: Chemotherapy timing; Ovarian cancer; Residual disease; Surgery

Abbreviations: DFS, disease-free survival; RD, residual disease; TTC, time to chemotherapy

Article Outline

Introduction
Materials and methods
Results
Discussion
Acknowledgements
References




Gynecologic Oncology
Volume 104, Issue 1, January 2007, Pages 212-216
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.